Kripto Al Piyasalar Spot Vadeli İşlemlerMU Birikim Etkinlik Merkezi

Daha Fazla

Widespread Reimbursement Advancements Recognize the Clinical Value of Plaque Analysis for Physicians and Patients BOSTON–(BUSINESS WIRE)–#CoronaryArteryDisease—Widespread Reimbursement Advancements Recognize the Clinical Value of Plaque Analysis for Physicians and Patients BOSTON–(BUSINESS WIRE)–#CoronaryArteryDisease—

Elucid Announces Broad Reimbursement for Quantitative Coronary Plaque Analysis

Yazar: AI Journal

Kaynak: AI Journal

2026/01/09 20:16

Okuma süresi: 4 dk

IQ$0.0007449-0.65%

PUBLIC$0.00857-8.53%

Bu içerikle ilgili geri bildirim veya endişeleriniz için lütfen [email protected] üzerinden bizimle iletişime geçin.

Widespread Reimbursement Advancements Recognize the Clinical Value of Plaque Analysis for Physicians and Patients

BOSTON–(BUSINESS WIRE)–#CoronaryArteryDisease—Elucid today announced that, effective January 1, 2026, its Plaque-IQ coronary plaque analysis has received a new Category I Current Procedural Terminology (CPT®) designation, alongside increasingly widespread coverage and reimbursement from both public and private payors. Together, these developments underscore the clinical value of coronary plaque analysis and establish favorable conditions for broader adoption of the technology.

Quantitative coronary plaque analysis, such as Elucid’s Plaque-IQ, is now reportable under Category I CPT code 75577, with a national average payment amount of $1,012 for use in imaging centers and physician offices. For hospital outpatient settings, the 2026 Outpatient Prospective Payment System (OPPS) rate has been set at $951. The establishment of CPT code 75577 by the American Medical Association (AMA) provides a standardized code descriptor for quantitative assessment of coronary atherosclerotic plaque using coronary computed tomography angiography (CCTA).

This news is complemented by a coverage decision this week from Aetna, which will begin covering plaque analysis immediately. Aetna’s decision follows similar coverage decisions by Humana, Cigna, and UnitedHealthcare, all aligned with guidelines issued in July 2025 by radiology benefit manager Evicore. Collectively, more than 70 percent of covered Americans now have coverage policies in place for coronary plaque analysis.

“Plaque analysis is quickly becoming an essential tool in my overall patient diagnosis and management, and its adoption will only accelerate as coverage continues to expand,” said Victor Marinescu, MD, a cardiologist at Midwest Cardiovascular Institute in Naperville, Illinois. “I’m particularly intrigued by Elucid‘s histology-based technology and Plaque-IQ’s ability to identify lipid rich necrotic core (LRNC). This additional insight is influencing my diagnostic decisions and shaping how I manage patient care.”

While other plaque analysis technologies are validated against a human eye, Elucid’s Plaque-IQ is the only plaque analysis technology validated in objective ground truth histology, the gold standard for plaque characterization. Powered by CT-Virtual Histology (CT-VH), Plaque-IQ noninvasively quantifies and classifies coronary plaque and its components – including LRNC – providing insights into high-risk plaque features associated with heart attack and stroke, measuring true disease rather than directional proxies.^1,2

This approach is designed to help physicians prioritize and personalize treatment based on actual coronary artery disease rather than population-based risk estimates.

“Elucid has long been committed to advancing clinically meaningful imaging analytics that support physician decision-making,” said Elucid CEO Kelly Huang, PhD. “The scope, scale and speed of these reimbursement changes are unprecedented, and highlight the clinical value that CT-derived coronary plaque analysis brings to physicians and their patients. These advances reinforce our belief that Plaque-IQ helps physicians make patient-specific decisions around medical management and intervention.”

About Elucid

Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary and carotid plaque buildup), the root cause of cardiovascular disease. The company’s Plaque-IQ image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. Plaque-IQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. Plaque-IQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid’s FFR_CT product, which is currently under development, is derived from Elucid’s plaque algorithm, resulting in concordance between plaque and FFR_CT. FFR_CT helps physicians identify coronary blockages and the extent of a patient’s ischemia non-invasively. For more information, visit elucid.com.

References:

1 https://www.ahajournals.org/doi/10.1161/01.ATV.20.5.1262
2 https://pubmed.ncbi.nlm.nih.gov/39600843/

Contacts

Media Contact:
Sam Choinski

Pazanga Health Communications

(860) 301-5058

[email protected]

Piyasa Fırsatı

IQ Fiyatı(IQ)

$0.0007452

$0.0007452$0.0007452

-0.75%

USD

IQ (IQ) Canlı Fiyat Grafiği

Sorumluluk Reddi: Bu sitede yeniden yayınlanan makaleler, halka açık platformlardan alınmıştır ve yalnızca bilgilendirme amaçlıdır. MEXC'nin görüşlerini yansıtmayabilir. Tüm hakları telif sahiplerine aittir. Herhangi bir içeriğin üçüncü taraf haklarını ihlal ettiğini düşünüyorsanız, kaldırılması için lütfen [email protected] ile iletişime geçin. MEXC, içeriğin doğruluğu, eksiksizliği veya güncelliği konusunda hiçbir garanti vermez ve sağlanan bilgilere dayalı olarak alınan herhangi bir eylemden sorumlu değildir. İçerik, finansal, yasal veya diğer profesyonel tavsiye niteliğinde değildir ve MEXC tarafından bir tavsiye veya onay olarak değerlendirilmemelidir.